Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. lowered its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 12.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,506 shares of the life sciences company’s stock after selling 3,114 shares during the quarter. Victory Capital Management Inc.’s holdings in Integra LifeSciences were worth $409,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Blue Trust Inc. raised its stake in Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after buying an additional 444 shares in the last quarter. CWM LLC raised its stake in Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after buying an additional 425 shares in the last quarter. Northwest Investment Counselors LLC acquired a new stake in Integra LifeSciences during the third quarter valued at approximately $73,000. Canada Pension Plan Investment Board acquired a new stake in Integra LifeSciences during the second quarter valued at approximately $114,000. Finally, Allspring Global Investments Holdings LLC raised its stake in Integra LifeSciences by 58.0% during the second quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock valued at $136,000 after buying an additional 1,711 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $24.58 on Friday. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $45.42. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of -273.30, a price-to-earnings-growth ratio of 0.83 and a beta of 1.08. The business has a 50 day simple moving average of $20.63 and a 200 day simple moving average of $24.01. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. During the same period in the prior year, the company posted $0.76 EPS. The business’s revenue for the quarter was down .4% compared to the same quarter last year. On average, equities research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on IART. Citigroup upped their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Truist Financial lowered their target price on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a report on Monday, October 14th. Finally, Bank of America lowered their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $24.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.